Buscador de publicaciones

La producción científica de nuestros investigadores es muy elevada. En 2022 se publicaron 1.629 artículos en revistas científicas con un factor de impacto global que superó los 15.000 puntos.

[Pharmacological interactions: a professional challenge].

PMID: 24951899
Revista: Farmacia hospitalaria : organo oficial de expresio
Año: 2014
Referencia: Farm Hosp. 2014 May 1;38(3):151-3. doi: 10.7399/fh.2014.38.3.7494.
Factor de impacto:
Tipo de publicación: Editorial en revista nacional
Autores: Girona Brumos, L; Juarez Gimenez, J C; Lalueza Broto, P et al.
DOI: 10.7399/fh.2014.38.3.7494

Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.

PMID: 25182512
Revista: DRUG DISCOV TODAY
Año: 2014
Referencia: Drug Discov Today. 2014 Dec;19(12):1928-35. doi: 10.1016/j.drudis.2014.08.004. Epub 2014 Aug 23.
Factor de impacto: 5.964
Tipo de publicación: Revisión en revista internacional
Autores: Montuschi, Paolo, Malerba, Mario, Santini, Giuseppe, Miravitlles, Marc et al.
DOI: 10.1016/j.drudis.2014.08.004

Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.

PMID: 25182512
Revista: DRUG DISCOVERY TODAY
Año: 2014
Referencia: Drug Discov Today. 2014 Dec;19(12):1928-35. doi: 10.1016/j.drudis.2014.08.004. Epub 2014 Aug 23.
Factor de impacto:
Tipo de publicación: Revisión en revista internacional
Autores: Malerba, Mario; Miravitlles, Marc; Montuschi, Paolo; Santini, Giuseppe et al.
DOI: 10.1016/j.drudis.2014.08.004

[Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome].

PMID: 25555009
Revista: MEDICINA-BUENOS AIRE
Año: 2014
Referencia: Medicina (B Aires). 2014;74(6):474-5.
Factor de impacto: 0.421
Tipo de publicación: Artículo en revista nacional
Autores: Pinal-Fernandez, Iago, Garrigasait Vilaseca, Vanesa, Fernandez-Codina, Andreu, Aranda Rodriguez, Santiago et al.
DOI:

[Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome].

PMID: 25555009
Revista: MEDICINA-BUENOS AIRES
Año: 2014
Referencia: Medicina (B Aires). 2014;74(6):474-5.
Factor de impacto:
Tipo de publicación: Artículo en revista nacional
Autores: Aranda Rodriguez, Santiago; Fernandez-Codina, Andreu; Garrigasait Vilaseca, Vanesa; Pinal-Fernandez, Iago et al.
DOI:

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

PMID: 24744161
Revista: CANCER CHEMOTH PHARM
Año: 2014
Referencia: Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1. Epub 2014 Apr 18.
Factor de impacto: 2.571
Tipo de publicación: Artículo en revista internacional
Autores: Salazar, Ramon, Morales, Serafin, Gil-Martin, Marta, Aguirre, Elena, Oaknin, Ana, Garcia, Margarita, Callies, Sophie, Wickremsinhe, Enaksha R, Benhadji, Karim A, Llombart, Antonio et al.
DOI: 10.1007/s00280-014-2457-1

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

PMID: 24744161
Revista: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Año: 2014
Referencia: Cancer Chemother Pharmacol. 2014 Jun;73(6):1205-15. doi: 10.1007/s00280-014-2457-1. Epub 2014 Apr 18.
Factor de impacto:
Tipo de publicación: Artículo en revista internacional
Autores: Aguirre, Elena; Benhadji, Karim A; Callies, Sophie; Garcia, Margarita; Gil-Martin, Marta; Llombart, Antonio; Morales, Serafin; Oaknin, Ana; Salazar, Ramon; Wickremsinhe, Enaksha R et al.
DOI: 10.1007/s00280-014-2457-1

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 24652201
Revista: INVEST NEW DRUG
Año: 2014
Referencia: Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
Factor de impacto: 2.927
Tipo de publicación: Artículo en revista internacional
Autores: Brana, Irene, Siu, Lillian L, De Jonge, Maja J, Homji, Natasha, Mills, David, Di Tomaso, Emmanuelle, Sarr, Celine, Trandafir, Lucia, Massacesi, Cristian, Eskens, Ferry et al.
DOI: 10.1007/s10637-014-0082-9

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 24652201
Revista: INVESTIGATIONAL NEW DRUGS
Año: 2014
Referencia: Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. Epub 2014 Mar 21.
Factor de impacto:
Tipo de publicación: Artículo en revista internacional
Autores: Bendell, Johanna C; Brana, Irene; De Jonge, Maja J; Di Tomaso, Emmanuelle; Eskens, Ferry; Homji, Natasha; Massacesi, Cristian; Mills, David; Rodon, Jordi; Sarr, Celine et al.
DOI: 10.1007/s10637-014-0082-9

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

PMID: 24496004
Revista: J THORAC ONCOL
Año: 2014
Referencia: J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
Factor de impacto: 5.8
Tipo de publicación: Artículo en revista internacional
Autores: Felip, Enriqueta, Martinez, Pablo, Janne, Pasi A, Cohen, Roger B, Laird, A Douglas, Mace, Sandrine, Engelman, Jeffrey A, Ruiz-Soto, Rodrigo, Rockich, Kevin, Xu, Jianbo et al.
DOI: 10.1097/JTO.0000000000000088

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

PMID: 24496004
Revista: Journal of Thoracic Oncology
Año: 2014
Referencia: J Thorac Oncol. 2014 Mar;9(3):316-23. doi: 10.1097/JTO.0000000000000088.
Factor de impacto:
Tipo de publicación: Artículo en revista internacional
Autores: Cohen, Roger B; Engelman, Jeffrey A; Felip, Enriqueta; Janne, Pasi A; Laird, A Douglas; Mace, Sandrine; Martinez, Pablo; Rockich, Kevin; Ruiz-Soto, Rodrigo; Shapiro, Geoffrey I et al.
DOI: 10.1097/JTO.0000000000000088

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

PMID: 24583798
Revista: CLIN CANCER RES
Año: 2014
Referencia: Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.
Factor de impacto: 8.193
Tipo de publicación: Artículo en revista internacional
Autores: Papadopoulos, Kyriakos P, Tabernero, Josep, Markman, Ben, Patnaik, Amita, Tolcher, Anthony W, Baselga, Jose, Shi, Weiliang, Egile, Coumaran, Ruiz-Soto, Rodrigo, Laird, A Douglas et al.
DOI: 10.1158/1078-0432.CCR-13-2403

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

PMID: 24583798
Revista: CLINICAL CANCER RESEARCH
Año: 2014
Referencia: Clin Cancer Res. 2014 May 1;20(9):2445-56. doi: 10.1158/1078-0432.CCR-13-2403. Epub 2014 Feb 28.
Factor de impacto:
Tipo de publicación: Artículo en revista internacional
Autores: Baselga, Jose; Egile, Coumaran; Laird, A Douglas; Lorusso, Patricia M; Markman, Ben; Miles, Dale; Papadopoulos, Kyriakos P; Patnaik, Amita; Ruiz-Soto, Rodrigo; Shi, Weiliang et al.
DOI: 10.1158/1078-0432.CCR-13-2403

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

PMID: 25142843
Revista: ONCOLOGIST
Año: 2014
Referencia: Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.
Factor de impacto: 4.54
Tipo de publicación: Artículo en revista internacional
Autores: Suarez, Cristina, Bellmunt, Joaquim, Pons, Francesc, Bonfill, Teresa, Beltran, Marta, Moya, Irene, Galtes, Susana, Albanell, Joan, Carles, Joan, Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2014-0072

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

PMID: 25142843
Revista: ONCOLOGIST
Año: 2014
Referencia: Oncologist. 2014 Sep;19(9):917-8. doi: 10.1634/theoncologist.2014-0072. Epub 2014 Aug 20.
Factor de impacto:
Tipo de publicación: Artículo en revista internacional
Autores: Albanell, Joan; Bellmunt, Joaquim; Beltran, Marta; Bonfill, Teresa; Carles, Joan; Gallardo, Enrique; Galtes, Susana; Moya, Irene; Pons, Francesc; Rodon, Jordi et al.
DOI: 10.1634/theoncologist.2014-0072

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

PMID: 24827126
Revista: ANN ONCOL
Año: 2014
Referencia: Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
Factor de impacto: 6.578
Tipo de publicación: Artículo en revista internacional
Autores: Balmana, J, Tung, N M, Isakoff, S J, Grana, B, Ryan, P D, Saura, C, Lowe, E S, Frewer, P, Winer, E, Baselga, J et al.
DOI: 10.1093/annonc/mdu187

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

PMID: 24827126
Revista: ANNALS OF ONCOLOGY
Año: 2014
Referencia: Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
Factor de impacto:
Tipo de publicación: Artículo en revista internacional
Autores: Balmana, J; Baselga, J; Frewer, P; Garber, J E; Grana, B; Isakoff, S J; Lowe, E S; Ryan, P D; Saura, C; Tung, N M et al.
DOI: 10.1093/annonc/mdu187

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

PMID: 24470511
Revista: CLIN CANCER RES
Año: 2014
Referencia: Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.
Factor de impacto: 8.193
Tipo de publicación: Ensayo clínico
Autores: Di Tomaso, Emmanuelle, Saura, Cristina, Bendell, Johanna, Jerusalem, Guy, Su, Shaun, Ru, Qinhua, De Buck, Stefan, Mills, David, Ruquet, Sophie, Bosch, Ana et al.
DOI: 10.1158/1078-0432.CCR-13-1070

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

PMID: 24470511
Revista: CLINICAL CANCER RESEARCH
Año: 2014
Referencia: Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.
Factor de impacto:
Tipo de publicación: Ensayo clínico
Autores: Baselga, Jose; Beck, Joseph T; Bendell, Johanna; Bosch, Ana; De Buck, Stefan; Di Tomaso, Emmanuelle; Dirix, Luc; Hirawat, Samit; Jerusalem, Guy; Massacesi, Cristian et al.
DOI: 10.1158/1078-0432.CCR-13-1070

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

PMID: 24570330
Revista: CANCER CHEMOTH PHARM
Año: 2014
Referencia: Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.
Factor de impacto: 2.571
Tipo de publicación: Artículo en revista internacional
Autores: Siguero, Mariano, Castellano, Daniel E, Bellmunt, Joaquim, Maroto, Jose Pablo, Font-Pous, Albert, Morales-Barrera, Rafael, Ghanem, Ismael, Suarez, Cristina, Martin Lorente, Cristina, Etxaniz, Olatz et al.
DOI: 10.1007/s00280-014-2419-7

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

PMID: 24570330
Revista: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Año: 2014
Referencia: Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26.
Factor de impacto:
Tipo de publicación: Artículo en revista internacional
Autores: Alfaro, Vicente; Bellmunt, Joaquim; Capdevila, Laia; Carles, Joan; Castellano, Daniel E; Coronado, Cinthya; Etxaniz, Olatz; Fernandez-Teruel, Carlos; Font-Pous, Albert; Ghanem, Ismael et al.
DOI: 10.1007/s00280-014-2419-7

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

PMID: 25270629
Revista: STROKE
Año: 2014
Referencia: Stroke. 2014 Nov;45(11):3304-10. doi: 10.1161/STROKEAHA.114.005835. Epub 2014 Sep 30.
Factor de impacto: 6.018
Tipo de publicación: Ensayo clínico
Autores: Urfer, Roman, Moebius, Hans J, Skoloudik, David, Santamarina, Estevo, Sato, Wakao, Mita, Shiro, Muir, Keith W et al.
DOI: 10.1161/STROKEAHA.114.005835

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

PMID: 25270629
Revista: STROKE
Año: 2014
Referencia: Stroke. 2014 Nov;45(11):3304-10. doi: 10.1161/STROKEAHA.114.005835. Epub 2014 Sep 30.
Factor de impacto:
Tipo de publicación: Ensayo clínico
Autores: Mita, Shiro; Moebius, Hans J; Muir, Keith W; Santamarina, Estevo; Sato, Wakao; Skoloudik, David; Urfer, Roman et al.
DOI: 10.1161/STROKEAHA.114.005835

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

PMID: 24081577
Revista: ANN HEMATOL
Año: 2014
Referencia: Ann Hematol. 2014 Jan;93(1):43-6. doi: 10.1007/s00277-013-1914-y. Epub 2013 Oct 1.
Factor de impacto: 2.396
Tipo de publicación: Ensayo clínico
Autores: Martinez-Cuadron, David, Montesinos, Pau, Oriol, Albert, Salamero, Olga, Vidriales, Belen, Bergua, Juan, Herrera, Pilar, Vives, Susanna, Sanz, Jaime, Carpio, Cecilia et al.
DOI: 10.1007/s00277-013-1914-y

Publicaciones

Buscador de publicaciones

[Pharmacological interactions: a professional challenge].

Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.

Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping.

[Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome].

[Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome].

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy.

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Phase II clinical trial of PM00104 (Zalypsis((R))) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke.

Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.

Patronato:

Colabora:

Acreditaciones: